2016, Volume 18, Issue 4
Strategic Study of CAE >> 2016, Volume 18, Issue 4 doi: 10.15302/J-SSCAE-2016.04.007
Advanced Bioprocess Development and Manufacturing Technologies in High-Throughput Miniature Bioreactors
1. Boston Institute of Biotechnology, LLC, Southborough, MA 01772, USA;
2. Beijing University of Chemical Technology, Beijing 100029, China
Next Previous
Abstract
In recent years, the importance of rapid response time to virulent infectious disease is widely recognized. However, the traditional technologies for bioprocess development and manufacturing will not succeed in winning this war. US healthcare companies and related organizations including US Department of Human Health and Service, proposed and started working on the next generation of technology platforms for advanced bioprocess development and manufacturing (ABDM).The development of ABDM is to significantly reduce the timeframe for bioprocess development and manufacturing, making it possible to promptly respond to outburst of pandemic influenza and prevent it from outspreading. Meanwhile, the development of precision medicine also presents new demands to the biopharmaceutical industry. With the demand of small-scale production and fast turn-around time of precision medicine, the duration of development and manufacturing needs to be accelerated significantly. At the same time, the number of sub-groups of the product would increase, and the batch sizes and amount of final product would decrease, as well. To satisfy the demands of small-scale production and fast turnaround time of ABDM, micro- and mini-bioreactor is the key equipment. The major technologies of ABDM include high throughput screening and process development based on micro- and mini-bioreactors, disposable technology, modular unit operations and flexible manufacturing. The development of ABDM will directly strengthen the National Security, improve the welfare of the people, and it also provides great social and economic values. The impact of this platform will radiate to the entire biomanufacture industry, and open a whole new era for the bioprocess development and bio-manufacturing.
Keywords
advance bioprocess development and biomanufacturing ; virulent infectious disease ; precision medicine ; miniature bioreactor ; high throughput technology ; disposable technology
Figures
Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.
Fig. 5.
References
[ 1 ] Taubenberger J K, Morens D M. 1918 Influenza: the mother of all pandemics [J]. Emerging Infectious Disease, 2006, 12 (1): 15–22. link1
[ 2 ] The latest news on H7N9 avian influenza: 15 people in Guangdong died and more than hundreds people died in China [N/OL]. Inter-national Business Times, 2014-02-21 [ 2016-05-28]. http://www.ibtimes.com.cn/articles/35575/20140221/28192.htm. Chinese. link1
[ 3 ] United States Government Accountability Office. GAO-14-329 National Preparedness: HHS has funded flexible manufacturing activities for medical countermeasures, but it is too soon to assess their effect [R]. Washington, D.C.: GAO, 2014.
[ 4 ] The U.S. Department of Health and Human Services. Advanced development of recombinant influenza vaccine products and man-ufacturing capabilities for pandemic preparedness [R/OL]. Wash-ington DC: Department of Health and Human Services, 2009.
[ 5 ] The U.S.Department of Health and Human Services. Fiscal year 2015 work plan (mid-year update) [R/OL]. 2015 [2016-05-28].
[ 6 ] The Office of the Press Secretary of the White House. Fact sheet—middle class economics: The president’s fiscal Year 2016 budget (investing in American Innovation) [EB/OL]. (2015-02-02) [2016-05-28].
[ 7 ] Collins F S, Varmus H. A new initiative on precision medicine [J]. The New England Journal of Medicine, 2015, 372 (9): 793–795. link1
[ 8 ] Herbert M. Revolutionising the manufacture of precision medi-cines [EB/OL]. (2015-06-23) [2016-05-28].
[ 9 ] Kaplan D. National Science Foundation(NSF) Workshop Report—advanced biomanufacturing [C/OL].
[10] Jiao P. Strain screening and early fermentation process develop-ment platform based on minibioreactors [J]. Biotechnology & Business, 2015, 1 (1): 17–23. Chinese. link1
[11] Ngibuini M. Automated mini bioreactor technology for microbial and mammalian cell culture: flexible strategy to optimize early process development of biologics and vaccines [J]. Bioprocess International, 2014 (9): 20–25.
[12] Jiao P. Recent advanced disposable technologies and single-use bioreactor in biotechnology field [J]. Biotechnology & Business, 2013, 3 (2): 46–50. Chinese. link1
[13] Galliher P M. Review of single use technologies in biomanufac-Fig. 5. DASbox mini-bioreactor.055Strategic Study of CAE 2016 Vol. 18 No. 4turing [R/OL]. 2007 [2016-05-28]. link1
[14] Wilson G. Evaluation of a novel micro-bioreactor system for cell culture optimization [C]. In: Smith R, editor. Cell technology for cell products. Proceedings of the 19th ESACT meeting, Dordrecht: Springer, 2005: 611. link1
[15] Warr S R, Betts J P, Ahmad S, et al. Streamlined process devel-opment using the mircro-24 bioreactor system [J]. BMC Proceed-ings, 2013, 7 (suppl 6): 1–3. link1
[16] Innovate UK. High Throughput Technologies (HTT) [EB/OL]. [2016-05-28].
京公网安备 11010502051620号
